Retatrutide Clinical Trials: What the Phase 2 Study Covered

Retatrutide was evaluated in a Phase 2 clinical trial published in The New England Journal of Medicine, with the highest weekly dose set at 12 mg over a 48-week treatment period. Detailed efficacy figures are available in the published trial for clinicians and researchers reviewing the primary literature.

Cross-trial comparisons between retatrutide, semaglutide, and tirzepatide are not reliable because the studies used different patient populations, treatment durations, and endpoints. No randomized head-to-head trial has compared these medications in the same population.

The trial tested five weekly dose levels: 1 mg, 2 mg, 4 mg, 8 mg, and 12 mg, alongside a placebo group. The study was designed to assess how outcomes related to dose level across the 48-week treatment period.

The full set of dose-by-dose outcomes is reported in the published Phase 2 trial in The New England Journal of Medicine. Patients interested in treatment options should discuss currently available, FDA-reviewed medications with a licensed provider rather than rely on investigational-drug trial figures.

The three medications differ primarily in how many receptors they target:

Semaglutide targets a single receptor (GLP-1).

Tirzepatide targets two receptors (GLP-1 + GIP).

Retatrutide targets three receptors (GLP-1 + GIP + glucagon) and remains investigational.

These are distinct molecules studied in separate clinical programs with different patient populations, durations, and endpoints. The glucagon receptor component is the distinguishing feature of the triple-agonist approach and is associated with effects on energy expenditure. Efficacy figures for each medication are reported in their respective published trials.

Several caveats apply to Phase 2 data. Phase 2 trials are smaller than Phase 3 pivotal trials and may not fully represent the results that will be seen in broader populations. The retatrutide Phase 2 trial enrolled approximately 340 participants.

Direct cross-trial comparisons have limitations. The studies used different patient populations, durations, and endpoints. A true head-to-head comparison would require a randomized trial testing retatrutide against semaglutide and tirzepatide in the same population -- such a study has not been conducted.

The 48-week duration is also shorter than the durations used in some other GLP-1-class pivotal trials, which further limits cross-trial comparison. Longer-term outcomes for retatrutide remain to be characterized in Phase 3.

Threshold analyses -- the proportion of participants reaching specific weight-loss levels -- are a standard metric reported in obesity trials and are detailed in the published Phase 2 data. These analyses matter because certain health benefits, such as diabetes remission and cardiovascular risk reduction, are generally more likely at higher weight-loss levels.